Post-market Review of Pulmonary Arterial Hypertension (PAH) Medicines – Public Consultation

Page last updated: 10 February 2017

The public submission process is now open for the Post-market Review of Pulmonary Arterial Hypertension (PAH) Medicines.

Interested organisations and individuals are invited to provide a submission addressing the Review’s Terms of Reference.  To make a submission please go to the PAH Public Consultation page.

The public submission process will be open for 6 weeks and will close at 5pm AEDT Monday, 27 March 2017.      

Further information on the Review is available on the PAH Review page.